PreClinical Studies

Study title:

“Efficacy and safety study of “KSM-66 ashwagandha” in Swiss Albino mice”

Details:

This study was performed to assess the efficacy of KSM-66 ashwagandha, when given for 28 consecutive days to Swiss Albino Mice by oral route.

 

No.of mice taken for the study : 72 (Male 36 and Female 36)
Duration of study : 28 days

Results:

  1. KSM-66 ashwagandha administered group showed statistically significant increase in the Neutrophil counts compared to control and cyclophosphamide group.

  2. KSM-66 exhibited significant protection from neutropenia at much lower dosages as compared to other extract (hydro-alcoholic) of ashwagandha

  3. KSM-66 prevented cyclophosphamide induced neutropenia in mice, thereby acting as an immunomodulatory agent, which may be used during chemotherapy and radiotherapy.

  4. There was a significant indication of spleen lymphocyte proliferation activity in mice during this study.

  5. Protective effect of KSM-66 on drug induced neutropenia, strongly suggests that this drug may be used as a potent immunomodulator.

  6. It was also found that KSM-66 was clinically well tolerated up to 1300 mg/kg bodyweight when administered orally to Swiss albino mice for 14 days
  7. CPA = Cyclophosphamide